Anthem Biosciences Limited (NSE: ANTHEM) and Divis Laboratories Limited (NSE: DIVISLAB) are both listed in the Pharmaceutical CDMO and CRO Services industry. Anthem Biosciences has a market capitalisation of ₹47,055 Cr and Divis Laboratories ₹2,64,022 Cr, as of 9 Nov 2026. Their P/E ratios are 80.1 and 102.8 respectively. Return on equity is 19.45% for Anthem Biosciences and 16.19% for Divis Laboratories. Over one year, Anthem Biosciences's share price is up 36.4% and Divis Laboratories's is up 70.0%.
| Metric | Anthem Biosciences | Divis Laboratories |
|---|---|---|
| NSE Symbol | ANTHEM | DIVISLAB |
| BSE Code | 544449 | 532488 |
| Share Price | ₹959.00 | ₹11,565.50 |
| Market Cap | ₹47,055 Cr | ₹2,64,022 Cr |
| P/E Ratio | 80.1 | 102.8 |
| Return on Equity | 19.45% | 16.19% |
| Return on Assets | 14.20% | 10.07% |
| Dividend Yield | 0.24% | 0.30% |
| Beta (1Y) | 0.56 | 0.28 |
| 1-Year Price Change | +36.4% | +70.0% |
| 3-Month Price Change | +12.4% | +39.3% |
| 52-Week Range | ₹579.15 – ₹989.10 | ₹5,647.50 – ₹11,824.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹594 Cr | ₹3,676 Cr |
| Quarterly Net Profit | ₹211 Cr | ₹1,127 Cr |
| Net Margin | 35.6% | 30.7% |
| EPS (Basic, Quarter) | ₹3.75 | ₹42.49 |
| Results Basis | consolidated | consolidated |
| Headquarters | Bengaluru, Karnataka | Hyderabad, Telangana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to …
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Re…
Divis Laboratories has a market capitalisation of ₹2,64,022 Cr, against ₹47,055 Cr for Anthem Biosciences as of 9 Nov 2026, about 5.6 times the size by market cap.
Anthem Biosciences has a P/E of 80.1 and Divis Laboratories a P/E of 102.8 as of 9 Nov 2026.
Anthem Biosciences has a return on equity of 19.45% and Divis Laboratories 16.19%.
Anthem Biosciences's share price is up 36.4% over one year and Divis Laboratories's is up 70.0%.
Anthem Biosciences reported revenue of ₹594 Cr and net profit of ₹211 Cr for Q2 FY27. Divis Laboratories reported revenue of ₹3,676 Cr and net profit of ₹1,127 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.